Skip to main
HURA

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences is expected to see an increase in royalty fees and other revenues due to the company's unique technologies and promising pipeline. Additionally, the company's personalized cancer vaccine candidate, IFx-2.0, has the potential to overcome primary resistance to checkpoint inhibitors, making it a highly sought after treatment in the immuno-oncology market. The company's strong financial performance in the form of increasing revenues and zero selling and marketing expenses also suggest positive growth potential.

Bears say

TuHURA Biosciences is expected to face significant risks due to its high reliance on the success of its personalized cancer vaccine candidate IFx-2.0, which has a low probability of approval. In addition, the company's anti-Vista mAb in AML has an even lower chance of approval, reducing the overall potential market value for the company. These risks, combined with potential delays and competition in the market, raise concerns about the long-term viability and success of TuHURA Biosciences as a profitable company.

HURA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 3 analysts, HURA has a Strong Buy consensus rating as of May 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.